Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF) (2016 - 2025)

Ligand Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $8.2 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 4.79% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $33.8 million, down 4.15%, while the annual FY2025 figure was $33.8 million, 4.15% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $8.2 million at Ligand Pharmaceuticals, down from $8.3 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $13.7 million in Q1 2022 and bottomed at $8.2 million in Q4 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $9.2 million (2023), against an average of $10.4 million.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 267.18% in 2021 before it plummeted 36.11% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.2 million in 2021, then decreased by 15.45% to $11.1 million in 2022, then decreased by 19.93% to $8.9 million in 2023, then dropped by 3.24% to $8.6 million in 2024, then fell by 4.79% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Depreciation & Amortization (CF) are $8.2 million (Q4 2025), $8.3 million (Q3 2025), and $8.5 million (Q2 2025).